Release Date: December 6, 2016
Expiration Date: December 6, 2017
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to inform physicians about current and emerging data sets in the context of optimizing sequencing considerations in patients with ALK-positive non-small cell lung cancer (NSCLC).
Instructions for Participation/How to Receive Credit:
This activity is directed toward medical oncologists, pulmonary care specialists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with lung cancer. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers interested in the treatment of lung cancer are also invited to participate.
Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.
This activity is funded by Physicians' Education Resource®, LLC.
This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed.The information provided in this CME/CE activity is for continuing medical and nursing education purposes only andis not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
Minimum System Requirements (Mac OS)
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018